SVP, Technical Operations at Locana
Adam Fowler joined Locanabio in August 2020 as Senior Vice President of Technical Operations. Adam has a proven track record of successfully leading and supporting early-to-late stage CMC drug development activities with over 20 INDs and through the commercial approval process of 2 licensed biologic products (Ruconest® and Reblozyl®). Adam has extensive experience spanning a broad range of biologics process development, manufacturing and supply chain activities across multiple biologics modalities, including ~7 years in gene therapy, including roles in process development where he drove the development of and transfer of scalable processes for multiple viral vectors types (AAV, Lentivirus and Adenovirus) and programs, and later in a manufacturing capacity where he led internal manufacturing operations at Genzyme’s Gene Therapy Operations (GTO) manufacturing site (acquired from Cell Genesys in 2005). Prior to Locanabio, Adam spent ~4 years at Celgene (acquired by BMS in Nov 2019) as Senior Director of Biopharmaceutical Development and Manufacturing, where he led the group responsible for all outsourced biologics DS development and manufacturing activities for the entire Celgene protein biologics portfolio, and was involved in the US (2019) and EU (2020) approvals, and subsequent PAS approval (2020) for an additional DS manufacturing site, for Celgene’s first commercial biologic product Reblozyl®. Prior to Celgene, Adam was Vice President of CMC at AnaptysBio, where he established their initial CMC group, and led all CMC activities to get their first 2 products into the clinic, and previous to that, Adam led CMC for Salix Pharmaceuticals’ (Salix acquired San Diego-based Santarus in 2014) biologics programs, a tenure which included the BLA filing and 2014 FDA approval of Salix’s first biologic product RUCONEST®. Earlier in his career, Adam held development and manufacturing positions of increasing responsibility at) NexBio (now Ansun Biopharma), Genzyme, Cell Genesys and Eligix (acquired by BioTransplant in 2001). Adam received his B.S. and M.S. degrees in Biotechnology from Worcester Polytechnic Institute.
SVP, Technical Operations